The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISA 2022 | The promise of CRISPR-based gene editing therapy for hATTR amyloidosis
Marcus Anthony Urey, MD, University of California, San Diego, CA, talks on the potential of CRISPR-based gene-editing therapy for patients with hereditary transthyretin-mediated (hATTR) amyloidosis. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Alnylam, Akcea, BridgeBio
Honoraria: Pfizer
Research support: Ionis
